

ABRYSVO®

Active ingredient(s): recombinant respiratory syncytial virus pre-fusion F protein

Consumer Medicine Information

This leaflet provides important information about using ABRYSVO. **You should also speak to your healthcare professional if you would like further information or if you have any concerns or questions about using ABRYSVO.**

Where to find information in this leaflet:

1. Why am I being given ABRYSVO?
2. What should I know before I am given ABRYSVO?
3. What if I am taking other medicines?
4. How is ABRYSVO given?
5. What should I know after being given ABRYSVO?
6. Are there any side effects?
7. Product details

1. Why am I being given ABRYSVO?

ABRYSVO is a vaccine, which is a type of medicine that helps to protect (immunise) people from certain infectious diseases. It does this by preparing the body's defences to fight the infection before you catch the bacteria or virus.

ABRYSVO is used to prevent disease of the respiratory tract (lungs) caused by a virus called respiratory syncytial virus (RSV).

ABRYSVO contains a protein (antigen) from each of the two subgroups (A and B) of RSV.

RSV is a common virus which, in most cases, causes mild, cold-like

symptoms such as a sore throat, cough or a blocked nose. However, some individuals are at higher risk of respiratory disease caused by RSV. This includes young infants, older adults and those with chronic medical conditions such as heart or lung disease. In infants RSV can cause serious lung problems such as bronchiolitis and pneumonia. In older adults it can make existing conditions such as chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF) worse. It can lead to hospitalisation in severe cases, and in some cases it can be fatal.

ABRYSVO is given to:

- pregnant individuals to protect their infants from birth through 6 months of age, or
- individuals 60 years of age or older.

As with any vaccine, ABRYSVO may not fully protect all those who receive it.